Clinical Trial Goal
To find out if lenalidomide and teclistamab, in combination or alone, is safe and works well to treat multiple myeloma after autologous BMT
You may be able to join this trial if you:
- Are 18 years old or older
- Have newly diagnosed multiple myeloma
- Have had or plan to have autologous BMT
- Have not been treated with any of the following. Your doctor can tell you this:
- A drug that targets BCMA
- CAR T-cell therapy
- NK cell therapy
- Agree to have other standard tests done to see if you can be in the clinical trial
Trial Details
Lenalidomide is a drug that blocks growth of cancer cells.
Teclistamab is a bispecific antibody that targets BCMA and CD3 on certain cells.
In this trial, you’ll be randomized to 1 of 3 groups. Once you’re randomized, you'll be told what group you're in:
Teclistamab is a bispecific antibody that targets BCMA and CD3 on certain cells.
In this trial, you’ll be randomized to 1 of 3 groups. Once you’re randomized, you'll be told what group you're in:
- Group 1 – Lenalidomide plus teclistamab
- Group 2 – Lenalidomide
- Group 3 - Teclistamab
You’ll get:
- Lenalidomide – Group 1 and 2 only - A pill that you take by mouth. The dose you'll get depends on when you start the trial and how safe it has been
- Teclistamab – Group 1 and 3 only - Given as a shot under your skin. The dose you'll get depends on when you start the trial and how safe it has been
You'll have biopsies to see how well the treatment is working. The clinical trial doctors will check your health for up to 8 years.
The Food and Drug Administration (FDA) has approved all of the drugs used in this trial. Using them in this combination to treat newly diagnosed multiple myeloma after autologous BMT is new and unproven.
Contacts
Sabrin Tahri, +31 10 268 70 65, sabrin.tahri@emn.org
Sarah Lonergan, +31 10 268 70 65, sarah.lonergan@emn.org
Locations
Sponsors
collaborator: Janssen Pharmaceutica, lead: European Myeloma Network B.V.
